SCHEMBL5364206

SCHEMBL5364206

Cc1ccsc1C=C1C(=O)Nc2ccc(C(=O)OCc3ccccc3)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 5/20 0.47
▸ PDPK1 O15530 2/20 0.46
▸ MAPT P10636 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ PAK4 O96013 2/20 0.43
▸ AURKA O14965 1/20 0.43
▸ RAF1 P04049 1/20 0.43
▸ TLK2 Q86UE8 4/20 0.42
▸ KDR P35968 2/20 0.42
▸ PSEN1 P49768 1/20 0.42
▸ PSEN2 P49810 1/20 0.42
▸ APH1B Q8WW43 1/20 0.42
▸ NCSTN Q92542 1/20 0.42
▸ APH1A Q96BI3 1/20 0.42
▸ PSENEN Q9NZ42 1/20 0.42
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362148 0.88 KDR (0.48) JAK3PDPK1ALDH1A1AURKARAF1
SCHEMBL5366782 0.84 PDPK1 (0.60) JAK3PDPK1MAPTNPC1ALDH1A1
SCHEMBL5367344 0.83 GRK5 (0.51) JAK3ALDH1A1PAK4KDRMEN1
SCHEMBL5368790 0.82 TLK2 (0.66) JAK3PDPK1MAPTNPC1LMNA
SCHEMBL5366152 0.80 GSK3B (0.51) JAK3MAPTSMN1; SMN2PAK4TLK2
SCHEMBL5364938 0.79 PDPK1 (0.70) JAK3PDPK1PAK4TLK2KDR
SCHEMBL5359359 0.77 TLK2 (0.47) JAK3PDPK1MAPTNPC1ALDH1A1
SCHEMBL5367680 0.76 PDGFRB (0.70) NPC1RAB9ATLK2KDRKMT2A
SCHEMBL5358278 0.76 MEN1 (0.46) PDPK1MAPTNPC1ALDH1A1RAB9A
SCHEMBL5727507 0.74 KDR (0.71) JAK3PDPK1MAPTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 — — US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 — — US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK JAK3 40/4885PDPK1 31/4885MAPT 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback